Metabolic Tumor Heterogeneity Hints at NSCLC PrognosisMetabolic Tumor Heterogeneity Hints at NSCLC Prognosis
Can glucose metabolic heterogeneity signal prognosis in non-small cell lung cancer (NSCLC) patients treated with erlotinib? Medscape Radiology
Publication date: Available online 20 May 2019Source: Journal of Geriatric OncologyAuthor(s): Francesco Cuccia, Gianluca Mortellaro, Rosario Mazzola, Alessandra Donofrio, Vito Valenti, Antonella Tripoli, Domenica Matranga, Antonio Lo Casto, Giuseppe Failla, Giuseppe Di Miceli, Giuseppe FerreraAbstractObjectivesTo investigate whether assessment with two geriatric screening tools shows a correlation with clinical outcomes of patients aged 65 years or more, with early-stage Non-Small Cell Lung Cancer (es-NSCLC) treated with hypofractionated stereotactic radiotherapy.MethodsFrom March 2014 to June 2018 we retrospectively eva...
Conclusion We observed a significant increase in global lung inflammation bilaterally as measured by quantification of PG. However, no significant change in global lung inflammation was noted after proton therapy. Future larger studies are needed to determine whether this difference correlates with lower risks of radiation pneumonitis in NSCLC patients treated with proton therapy.
Condition: Non-small Cell Lung Cancer Intervention: Combination Product: NK cell and PD-1 antibody Sponsor: First Hospital of Jilin University Recruiting
Conclusion: Our studies suggested sequencing even a single, frequently mutated gene may provide insight into genome-wide mutational burden, and may serve as a biomarker to predict immune response.
CONCLUSION: To our knowledge this is the first study comparing the levels of protein and mRNA in the serum material of HGF, c-MET, EGF and EGFR parameters in lung cancer patients' blood samples. Further prospective studies with more participants for better understanding of mechanism and effect for HGF and c-MET inhibitors in lung cancer will help us to identify of these biomarkers role for guiding us to sellect individualized itargeted therapies. PMID: 31104010 [PubMed - as supplied by publisher]
ConclusionsNANOG and ALDH1 protein or mRNA expression showed improved prognosis in adenocarcinoma alone. ALDH1 expression correlated with an epithelial-like phenotype.
ConclusionsWe identified a pre-treatment c-miRNA signature prognostic for G3 + RICT. With further development, pre- and mid-treatment c-miRNA profiling could contribute to patient-specific dose selection and treatment adaptation.
Conclusion Central and peripheral lung squamous cell carcinoma showed clinical phenotype difference not only reflected in the incidence of lymph node metastasis, but also in gene expression profiles. Among them, HNF1A, CYP3A4, ALB, APOA1 at the key position of the differential gene interaction network and maybe as regulatory factors in the phenotypic difference. DOI: 10.3779/j.issn.1009-3419.2019.05.04
Background and objective Current research shows that platelet to lymphocyte ratio (PLR) has important prognostic value in renal cell carcinoma, esophageal cancer, gastric cancer, liver cancer and colon cancer. The aim of the study is to evaluate the prognostic value of PLR in non-small cell lung cancer (NSCLC) through meta-analysis. Methods Literature search for PubMed, EMBASE, Web of Science, Medline, Cochrane Library, China National Knowledge Internet (CNKI), China Biomedical Medicine disc (CBMdisc), VIP, Wanfang Database using computer electronic system to study the association between PLR and overall survival (OS) and ...
Conclusion The efficiency of targeting EGFR-TKIs on different types of rare or complex mutations was heterogeneous. The PFS may be better in patients that harbored complex mutations than those with single rare mutations. Further studies with larger sa mple size are necessary. Moreover, to discover novel therapeutic targets and develop new drugs are imminentfor those patientswith no response to the existing treatments. DOI: 10.3779/j.issn.1009-3419.2019.05.06